Products
MyNAD+
My Tirzer (Tirzepatide) is a prescription-only injection medical product indicated for use in combination with diet and exercise to help improve blood sugar control (glycaemic control) in adults. Tirzepatide is a dual mechanism, activating both Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors. It enhances metabolic control by increasing insulin secretion in a glucose-dependent manner, reducing appetite, and slowing gastric emptying.
MY TIRZER is used to:
- Type 2 Diabetes Mellitus
Improve blood glucose control in adults, through enhanced insulin secretion
and reduced blood sugar levels.
- Support Weight Management
Reducing appetite,
delaying gastric emptying, and assisting in the
maintenance of weight loss in adults with obesity.
Key Benefits
Clinical efficacy outcomes are based on controlled
clinical trials. Individual patient response may vary.
Glycaemic Control
In the SURPASS clinical trial programme, Tirzepatide
demonstrated substantial reductions in HbA1c
compared with active comparators.
Mean HbA1c reductions ranged from 1.8% to 2.4% from baseline, with a high proportion of patients achieving HbA1c <7.0%.
A greater proportion of patients achieved glycaemic targets without clinically significant hypoglycaemia.
Mean HbA1c reductions ranged from 1.8% to 2.4% from baseline, with a high proportion of patients achieving HbA1c <7.0%.
A greater proportion of patients achieved glycaemic targets without clinically significant hypoglycaemia.
Weight Management
Tirzepatide has demonstrated clinically meaningful
weight reduction in adults with obesity when used in
conjunction with diet and lifestyle modification.
Clinical Trial Data (SURMOUNT-1): At Week 72, mean percentage body-weight reductions were observed as follows:
• 15.0% with 5 mg once weekly
• 19.5% with 10 mg once weekly
• 20.9% with 15 mg once weekly
• Compared with 3.1% in the placebo group
At higher doses, more than 50% of patients achieved ≥ 20% body-weight reduction.
Significant reductions in waist circumference were observed, consistent with loss of visceral adipose tissue.
Clinical Trial Data (SURMOUNT-1): At Week 72, mean percentage body-weight reductions were observed as follows:
• 15.0% with 5 mg once weekly
• 19.5% with 10 mg once weekly
• 20.9% with 15 mg once weekly
• Compared with 3.1% in the placebo group
At higher doses, more than 50% of patients achieved ≥ 20% body-weight reduction.
Significant reductions in waist circumference were observed, consistent with loss of visceral adipose tissue.
Why MyNAD+
Lower Contamination Risk
Freeze-dried formulation reduces risk of contamination.
Cost-Effective
Often more affordable than liquid alternatives.
Pure Ingredients
Contains fewer additives and preservatives.
Stable Formula
Powder form remains stable at room temperature, as it contains no water.
Extended Shelf Life
Lasts longer without spoiling compared to liquid forms.
Enhanced Absorption
Once mixed, the powder is quickly absorbed for faster results.
Flexible Dosing
Easily adjust your intake to match your personal needs.
Am I suitable for Tirzepatide?
What dosage do I need?
What side effects should I expect?
Does Tirzepatide really work?
Where can I access the product information?
Coming Soon
Stay tuned for updates on our new products.
